The genetic architecture of multiple myeloma (original) (raw)

• Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412–3420 (2005).
  Article PubMed Google Scholar
• Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21–33 (2003).
  Article PubMed Google Scholar
• Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007).
  Article CAS PubMed Google Scholar
• Akiyama, M. et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62, 3876–3882 (2002).
  CAS PubMed Google Scholar
• Chauhan, D. et al. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene 23, 3597–3602 (2004).
  Article CAS PubMed Google Scholar
• Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658–1667 (1999).
  CAS PubMed Google Scholar
• Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053–4062 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G. & Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42, 1564–1573 (2006).
  Article CAS PubMed Google Scholar
• Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046–1060 (2011).
  Article CAS PubMed Google Scholar
• Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–472 (2011). The first report of a myeloma genome, which demonstrated the complex and varied abnormalities that are seen in myeloma.
  Article CAS PubMed PubMed Central Google Scholar
• Gonzalez, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112–3121 (2007). A comprehensive review of normal antibody generation and plasma cell development, detailing the changes that are seen in MGUS and myeloma. The importance of SHM and CSR is highlighted.
  Article CAS PubMed Google Scholar
• Bergsagel, P. L. & Kuehl, W. M. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol. Rev. 194, 96–104 (2003). A review explaining the biological significance of chromosome 14 translocations in myeloma.
  Article CAS PubMed Google Scholar
• Hakim, O. et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 7 Feb 2012 (doi:10.1038/nature10909).
• Reimold, A. M. et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300–307 (2001).
  Article CAS PubMed Google Scholar
• Iwakoshi, N. N. et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature Immunol. 4, 321–329 (2003).
  Article CAS Google Scholar
• Shaffer, A. L. et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21, 81–93 (2004).
  Article CAS PubMed Google Scholar
• Davenport, E. L., Morgan, G. J. & Davies, F. E. Untangling the unfolded protein response. Cell Cycle 7, 865–869 (2008).
  Article CAS PubMed Google Scholar
• Carrasco, D. R. et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11, 349–360 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Bagratuni, T. et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 116, 250–253 (2010).
  Article CAS PubMed Google Scholar
• Oracki, S. A., Walker, J. A., Hibbs, M. L., Corcoran, L. M. & Tarlinton, D. M. Plasma cell development and survival. Immunol. Rev. 237, 140–159 (2010).
  Article CAS PubMed Google Scholar
• Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nature Rev. Immunol. 6, 741–750 (2006).
  Article CAS Google Scholar
• Chiecchio, L. et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 94, 1708–1713 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313–325 (2006).
  Article CAS PubMed Google Scholar
• Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56–e65 (2010).
  Article CAS PubMed Google Scholar
• Lopez-Corral, L. et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin. Cancer Res. 17, 1692–1700 (2011).
  Article CAS PubMed Google Scholar
• Cremer, F. W. et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet. Cytogenet. 161, 116–124 (2005).
  Article CAS PubMed Google Scholar
• Walker, B. A. et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms and genes important in the pathogenesis of multiple myeloma. Blood 108, 1733–1743 (2006).
  Article CAS PubMed Google Scholar
• Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011). An important paper discussing the role of intraclonal variation in tumour biology.
  Article CAS PubMed Google Scholar
• Sahota, S. S., Leo, R., Hamblin, T. J. & Stevenson, F. K. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood 87, 746–755 (1996).
  CAS PubMed Google Scholar
• Ross, F. M. et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19, 1634–1642 (2005).
  Article CAS PubMed Google Scholar
• Akiyama, M. et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187–6194 (2003).
  CAS PubMed Google Scholar
• Shammas, M. A. et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res. 10, 770–776 (2004).
  Article CAS PubMed Google Scholar
• Brennan, S. K. et al. Telomerase inhib ition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE 5, e12487 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• McKenna, R. W. et al. Plasma cell neoplasms. In World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (eds Swerdlow, S. H. et al.) 200–213 (IARC Press, 2008).
  Google Scholar
• Anderson, K. C. New insights into therapeutic targets in myeloma. ASH Education Book 2011, 184–190 (2011).
  Google Scholar
• Walker, B. A. et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553–562 (2011). The first report of global methylation changes from MGUS to PCL and within the myeloma cytogenetic subgroups.
  Article CAS PubMed Google Scholar
• Rasmussen, T. et al. Identification of translocation products but not K-RAS mutations in memory B cells from multiple myeloma patients. Haematologica 95, 1730–1737 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Altieri, A., Chen, B., Bermejo, J. L., Castro, F. & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661–1670 (2006).
  Article PubMed Google Scholar
• Broderick, P. et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nature Genet. 44, 58–61 (2012). The first GWAS to identify myeloma disease susceptibility loci.
  Article CAS Google Scholar
• Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296–303 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Chesi, M. et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674–681 (1996).
  CAS PubMed Google Scholar
• Shaughnessy, J. Jr et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98, 217–223 (2001).
  Article CAS PubMed Google Scholar
• Hurt, E. M. et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5, 191–199 (2004).
  Article CAS PubMed Google Scholar
• Shou, Y. et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl Acad. Sci. USA 97, 228–233 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Avet-Loiseau, H. et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98, 3082–3086 (2001).
  Article CAS PubMed Google Scholar
• Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167–180 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Carrasco, R. et al. Comprehensive genome-wide profile of regional gains and losses in multiple myeloma using array-CGH: The 1q21 amplification and potential role of the BCL-9 gene in multiple myeloma pathogenesis. Blood (ASH Annual Meeting Abstracts) 104, 785 (2004).
  Google Scholar
• Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12, 131–144 (2007). References 47 and 49 highlight the importance of NF-κB signalling in myeloma and the role that deregulation of the pathway has in myeloma pathogenesis.
  Article CAS PubMed PubMed Central Google Scholar
• Dickens, N. J. et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin. Cancer Res. 16, 1856–1864 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Boyd, K. D. et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res. 17, 7776–7784 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jenner, M. W. et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110, 3291–3300 (2007).
  Article CAS PubMed Google Scholar
• Leone, P. E. et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin. Cancer Res. 14, 6033–6041 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gonzalez-Paz, N. et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109, 1228–1232 (2007).
  Article CAS PubMed Google Scholar
• Dib, A., Barlogie, B., Shaughnessy, J. D. Jr & Kuehl, W. M. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 109, 1337–1338 (2007).
  Article CAS PubMed Google Scholar
• Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor-κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861–1874 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Onodera, N., McCabe, N. R. & Rubin, C. M. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 80, 203–208 (1992).
  CAS PubMed Google Scholar
• Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 10 (Suppl. 1), 117–126 (2005).
  Article CAS PubMed Google Scholar
• Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66–72 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, W. et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465, 473–477 (2010).
  Article CAS PubMed Google Scholar
• Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305–2315 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Aronson, L. I. et al. Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. ASH Annual Meeting Abstracts 116, 4083 (2010).
  Google Scholar
• Boyd, K. D. et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk. Lymphoma 51, 2126–2129 (2010).
  Article PubMed Google Scholar
• Fazzari, M. J. & Greally, J. M. Epigenomics: beyond CpG islands. Nature Rev. Genet. 5, 446–455 (2004).
  Article CAS PubMed Google Scholar
• Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer 10, 457–469 (2010).
  Article CAS Google Scholar
• Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nature Rev. Genet. 10, 295–304 (2009).
  Article CAS PubMed Google Scholar
• Nimura, K. et al. A histone H3 lysine 36 trimethyltransferase links Nkx2–5 to Wolf-Hirschhorn syndrome. Nature 460, 287–291 (2009).
  Article CAS PubMed Google Scholar
• Kim, J. Y. et al. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol. Cell Biol. 28, 2023–2034 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Marango, J. et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111, 3145–3154 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kuo, A. J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609–620 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211–220 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Brito, J. L. et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 94, 78–86 (2009).
  Article CAS PubMed Google Scholar
• Pei, H. et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124–128 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. 41, 521–523 (2009).
  Article CAS PubMed Google Scholar
• Avet-Loiseau, H. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630–4634 (2010).
  Article CAS PubMed Google Scholar
• Lode, L. et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95, 1973–1976 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Boyd, K. D. et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 50, 765–774 (2011).
  Article CAS PubMed Google Scholar
• Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA 105, 12885–12890 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Pichiorri, F. et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367–381 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zenz, T. et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114, 2589–2597 (2009).
  Article CAS PubMed Google Scholar
• Benetatos, L. & Vartholomatos, G. Deregulated microRNAs in multiple myeloma. Cancer 118, 878–887 (2012).
  Article CAS PubMed Google Scholar
• Chang, T. C. et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genet. 40, 43–50 (2008).
  Article CAS PubMed Google Scholar
• Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26, 349–355 (2012). Evidence is presented highlighting the importance of combining cytogenetic abnormalities with other disease markers to accurately predict therapeutic response.
  Article CAS PubMed Google Scholar
• Ross, F. M. et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95, 1221–1225 (2010).
  Article PubMed PubMed Central Google Scholar
• Chauhan, D. et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 87, 1104–1112 (1996).
  CAS PubMed Google Scholar
• Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148–3157 (2004).
  Article CAS PubMed Google Scholar
• Neri, P. et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 117, 6202–6213 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Annunziata, C. M. et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117, 2396–2404 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, P. et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin. Cancer Res. 17, 6347–6355 (2011).
  Article CAS PubMed Google Scholar
• Bezieau, S. et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat. 18, 212–224 (2001).
  Article CAS PubMed Google Scholar
• Braga, V. M., Betson, M., Li, X. & Lamarche-Vane, N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol. Biol. Cell 11, 3703–3721 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Allan, V. J. Cytoplasmic dynein. Biochem. Soc. Trans. 39, 1169–1178 (2011).
  Article CAS PubMed Google Scholar
• Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989–1999 (2010).
  Article CAS PubMed Google Scholar
• Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483–2494 (2003).
  Article CAS PubMed Google Scholar
• Vallet, S. et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl Acad. Sci. USA 107, 5124–5129 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Avet-Loiseau, H. et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109, 3489–3495 (2007).
  Article CAS PubMed Google Scholar
• Avet-Loiseau, H. et al. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 27, 4585–4590 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, G. J. et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118, 1231–1238 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Paiva, B. et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119, 687–691 (2012).
  Article CAS PubMed Google Scholar
• Munshi, N. C. et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117, 4696–4700 (2011). An international consensus statement discussing the clinical impact of cytogenetic abnormalities.
  Article CAS PubMed PubMed Central Google Scholar
• Broyl, A. et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543–2553 (2010).
  Article CAS PubMed Google Scholar
• Zhan, F. et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101, 1128–1140 (2003).
  Article CAS PubMed Google Scholar
• Nair, B. et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood 113, 6572–6575 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chng, W. J., Glebov, O., Bergsagel, P. L. & Kuehl, W. M. Genetic events in the pathogenesis of multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 571–596 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Kassambara, A. et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 18 Nov 2011 (doi:10.3324/haematol.2011.046821).
• Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020–2028 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Shaughnessy, J. D. Jr et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276–2284 (2007).
  Article CAS PubMed Google Scholar
• Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7–15 (2012).
  Article CAS PubMed Google Scholar
• Neben, K. et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119, 940–948 (2012).
  Article CAS PubMed Google Scholar
• Stewart, A. K. Whole genome sequencing in high-risk myeloma. 13th Annual International Myeloma Workshop 2011 [online] (2011).
  Google Scholar
• Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rettig, M. B. et al. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4-34) gene. Blood 87, 2846–2852 (1996).
• Nobuyoshi, M. et al. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. Br. J. Haematol. 77, 523–528 (1991).
  Article CAS PubMed Google Scholar
• Perez-Rosado, A. et al. BCL6 represses NFκB activity in diffuse large B-cell lymphomas. J. Pathol. 214, 498–507 (2008).
  Article CAS PubMed Google Scholar